Literature DB >> 22504749

Hepatic encephalopathy.

D Patel1, M J W McPhail, J F L Cobbold, S D Taylor-Robinson.   

Abstract

Hepatic encephalopathy is a serious and potentially fatal complication of both acute and chronic liver disease, arising as a result of hepatocellular failure, cirrhosis and/or portal-systemic shunting (Ferenci et al, 2002). It reflects a broad spectrum of neuropsychiatric abnormalities, encompassing a range of defects in psychomotor, locomotive, cognitive, emotional and behavioural functions (Prakash and Mullen, 2010). Hepatic encephalopathy is either overt or minimal. While overt hepatic encephalopathy can be diagnosed using bedside clinical tests, minimal hepatic encephalopathy is clinically invisible and requires psychometric testing to diagnose. The rising prevalence of end-stage viral hepatitis-related liver disease, coupled with the growing problem of alcoholic and non-alcoholic fatty liver disease, has significantly increased the burden of disease from cirrhosis (Mooney et al, 2007; Fleming et al, 2008), so recognition and appropriate management of the manifestations of decompensating cirrhosis (including hepatic encephalopathy) is essential. Hepatic encephalopathy has a substantial societal burden because of its impact on survival, quality of life and daily functioning, including an impaired ability to drive, leaving patients especially vulnerable to road traffic accidents (Ferenci et al, 2002; Prakash and Mullen, 2010).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504749     DOI: 10.12968/hmed.2012.73.2.79

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN: 1750-8460            Impact factor:   0.825


  11 in total

1.  Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies.

Authors:  Arumugam R Jayakumar; Xiao Y Tong; Kevin M Curtis; Roberto Ruiz-Cordero; Nagarajarao Shamaladevi; Missa Abuzamel; Joshua Johnstone; Gabriel Gaidosh; Kakulavarapu V Rama Rao; Michael D Norenberg
Journal:  J Neurochem       Date:  2014-08-01       Impact factor: 5.372

2.  Acute liver failure-induced hepatic encephalopathy s associated with changes in microRNA expression rofiles in cerebral cortex of the mouse [corrected].

Authors:  Raghu Vemuganti; Vinícius R Silva; Suresh L Mehta; Alan S Hazell
Journal:  Metab Brain Dis       Date:  2014-05-27       Impact factor: 3.584

Review 3.  Baroreflex functionality in the eye of diffusion tensor imaging.

Authors:  Ching-Yi Tsai; Yan-Yuen Poon; Julie Y H Chan; Samuel H H Chan
Journal:  J Physiol       Date:  2018-11-02       Impact factor: 5.182

Review 4.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

5.  RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Authors:  Christian Schulz; Kerstin Schütte; Siegfried Kropf; Friedhelm C Schmitt; Riccardo Vasapolli; Leon M Kliegis; Antonia Riegger; Peter Malfertheiner
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

6.  MRI/DTI of the Brain Stem Reveals Reversible and Irreversible Disruption of the Baroreflex Neural Circuits: Clinical Implications.

Authors:  Chia-Hao Su; Ching-Yi Tsai; Alice Y W Chang; Julie Y H Chan; Samuel H H Chan
Journal:  Theranostics       Date:  2016-04-11       Impact factor: 11.556

7.  A longitudinal study of patients with cirrhosis treated with L-ornithine L-aspartate, examined with magnetization transfer, diffusion-weighted imaging and magnetic resonance spectroscopy.

Authors:  Vijay P B Grover; Mark J W McPhail; Marzena Wylezinska-Arridge; Mary M E Crossey; Julie A Fitzpatrick; Louise Southern; Brian K Saxby; Nicola A Cook; I Jane Cox; Adam D Waldman; Novraj S Dhanjal; Aluel Bak-Bol; Roger Williams; Marsha Y Morgan; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2016-08-03       Impact factor: 3.584

8.  Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.

Authors:  Meritxell Ventura-Cots; Mar Concepción; José Antonio Arranz; Macarena Simón-Talero; Maria Torrens; Albert Blanco-Grau; Inma Fuentes; Pilar Suñé; Edilmar Alvarado-Tapias; Cristina Gely; Eva Roman; Beatriz Mínguez; German Soriano; Joan Genescà; Juan Córdoba
Journal:  Therap Adv Gastroenterol       Date:  2016-07-26       Impact factor: 4.409

9.  Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data.

Authors:  Hao Wu; Miao Liu; Jiajun Zhuang
Journal:  Exp Ther Med       Date:  2018-03-06       Impact factor: 2.447

10.  Morphological changes of cortical pyramidal neurons in hepatic encephalopathy.

Authors:  Jeng-Rung Chen; Bing-Ning Wang; Guo-Fang Tseng; Yueh-Jan Wang; Yong-San Huang; Tsyr-Jiuan Wang
Journal:  BMC Neurosci       Date:  2014-01-17       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.